Sterinova, headquartered in Saint-Hyacinthe, Quebec, Canada, has been launched as a new pharmaceutical company specializing in the development and manufacture of sterile ready-to-use injectable products. The new company is the result of a total investment of approximately $70 million, made by the following: the Fonds de solidarité FTQ, a development capital organization; Quebec Manufacturing Fund, on investment fund focused on manufacturing; Saint-Hyacinthe Technopole, an economic development organization through the Pharmaceutical Development Center and the City of Saint-Hyacinthe for guarantee funding; Desjardins, an association of credit unions; Investissement Québec, a financing corporation; and Canada Economic Development for Quebec Regions, a federal agency for business development. 

Sterinova’s Saint-Hyacinthe production site has been approved by Health Canada since 2015 for the manufacture of sterile biological products. The building of 6,225 square meters (67,000 square feet) was planned to allow a doubling in size. The plant is equipped with fully automated equipment and meets Canadian cGMP with a goal of meeting European and American requirements.

Source: Sterinova